ABVC BioPharma Inc Says In Nov 12, Co And Unit Each Entered Into A Multi-Year, Global Licensing Agreement With AiBtl BioPharma Inc; As Per Each Of The Respective Agreements, Each Of ABVC And Biolite Shall Receive 23M Shares Of Aibl Stock
Portfolio Pulse from Benzinga Newsdesk
ABVC BioPharma Inc and its unit Biolite have each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. According to the agreements, ABVC and Biolite will each receive 23 million shares of AiBtl stock, as disclosed in an SEC 8K filing.
November 16, 2023 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ABVC BioPharma Inc has entered into a global licensing agreement with AiBtl BioPharma Inc, which will result in ABVC receiving 23 million shares of AiBtl stock.
The licensing agreement is likely to be viewed positively by investors as it represents a strategic expansion and potential revenue stream for ABVC. Receiving 23 million shares of AiBtl stock could significantly increase ABVC's asset base and future earnings potential, which may lead to a short-term increase in ABVC's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100